LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

Apellis Pharmaceuticals Inc

Închisă

SectorSănătate

17.68 -0.39

Rezumat

Modificarea prețului

24h

Curent

Minim

17.42

Maxim

17.86

Indicatori cheie

By Trading Economics

Venit

-56M

-92M

Vânzări

-46M

167M

EPS

-0.74

Marjă de profit

-55.292

Angajați

705

EBITDA

-56M

-80M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+101.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-190M

2.4B

Deschiderea anterioară

18.07

Închiderea anterioară

17.68

Sentimentul știrilor

By Acuity

17%

83%

27 / 381 Clasament în Healthcare

Apellis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 iun. 2025, 18:52 UTC

Câștiguri

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

20 iun. 2025, 16:15 UTC

Achiziții, Fuziuni, Preluări

Canadian Natural Selling Control of Gas Plant to Secure Approval for Schlumberger Deal

20 iun. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

20 iun. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

20 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 iun. 2025, 20:13 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 iun. 2025, 20:11 UTC

Market Talk

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 iun. 2025, 19:56 UTC

Market Talk

Crude Oil Slips to End Week -- Market Talk

20 iun. 2025, 18:35 UTC

Market Talk

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 iun. 2025, 18:12 UTC

Market Talk

Gold Slides to Close Shortened Week -- Market Talk

20 iun. 2025, 17:56 UTC

Market Talk

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 iun. 2025, 17:50 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 iun. 2025, 17:35 UTC

Achiziții, Fuziuni, Preluări

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 iun. 2025, 17:30 UTC

Market Talk
Câștiguri

Adobe's AI Headwinds Seen Fading -- Market Talk

20 iun. 2025, 17:03 UTC

Câștiguri

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 iun. 2025, 16:50 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

20 iun. 2025, 16:50 UTC

Market Talk
Câștiguri

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 iun. 2025, 16:44 UTC

Achiziții, Fuziuni, Preluări

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 iun. 2025, 16:40 UTC

Market Talk
Câștiguri

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

20 iun. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

20 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 iun. 2025, 16:17 UTC

Achiziții, Fuziuni, Preluări

UniCredit: ULI and UVA Are Expected to Merge in 2026

20 iun. 2025, 16:17 UTC

Achiziții, Fuziuni, Preluări

UniCredit: Alessandro Santoliquido has been appointed CEO of both companies alongside his role as Head of Group Insurance

20 iun. 2025, 16:05 UTC

Market Talk

Gold Futures on Track to End Week Lower Despite Haven Demand -- Market Talk

20 iun. 2025, 15:56 UTC

Market Talk
Câștiguri

Accenture Says Federal Business Had Immaterial Impact to Growth -- Market Talk

20 iun. 2025, 15:26 UTC

Market Talk

Natural Gas Slips After Streak of Higher Closes -- Market Talk

20 iun. 2025, 15:25 UTC

Achiziții, Fuziuni, Preluări

Regulator Says Satisfied Sale Would Preserve Competition in Area Around Seiu Processing Plant

20 iun. 2025, 15:25 UTC

Achiziții, Fuziuni, Preluări

Competition Bureau Says Canadian Natural to Sell 75% Stake in Seiu Lake Natural Gas Plant to North 40 Resources

20 iun. 2025, 15:25 UTC

Achiziții, Fuziuni, Preluări

Canada Antitrust Regulation Reaches Agreement With Canadian Natural Resources Over Proposed Buy of Schlumberger JV Interest

20 iun. 2025, 15:09 UTC

Market Talk

Canadian Retail Sales Show Reversal of Tariff Front-Running -- Market Talk

Comparație

Modificare preț

Apellis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

101.53% sus

Prognoză pe 12 luni

Medie 35.65 USD  101.53%

Maxim 60 USD

Minim 18 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruApellis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

10

Cumpărare

8

Păstrare

0

Vânzare

Sentiment

By Acuity

27 / 381 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.